Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.46 |
| ▸ | PADI1 | Q9ULC6 | 4/20 | 0.46 |
| ▸ | PADI4 | Q9UM07 | 4/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.46 |
| ▸ | PADI2 | Q9Y2J8 | 3/20 | 0.46 |
| ▸ | PADI3 | Q9ULW8 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80453 | 1.00 | BCHE (0.47) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL15739025 | 0.99 | BCHE (0.46) | BCHEACHECYP26A1PADI1PADI4 | |
| Hydrochloric Acid SCHEMBL538996 | 0.99 | BCHE (0.46) | BCHEACHECYP26A1PADI1PADI4 | |
| Hydrochloric Acid SCHEMBL11325263 | 0.99 | BCHE (0.46) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL1396385 | 0.91 | BCHE (0.48) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL15271466 | 0.91 | BCHE (0.48) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL158087 | 0.91 | CA1 (0.54) | CYP26A1PADI1PADI4PDE4APADI2 | |
| SCHEMBL31206858 | 0.91 | CA1 (0.54) | CYP26A1PADI1PADI4PDE4APADI2 | |
| SCHEMBL16289858 | 0.91 | CA1 (0.54) | CYP26A1PADI1PADI4PDE4APADI2 | |
| Hydrochloric Acid SCHEMBL29401063 | 0.89 | CA1 (0.53) | CYP26A1PADI1PADI4PDE4APADI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4222255-A1 | METHOD FOR PRODUCING BETA-TRYPSIN | Ipsen Biopharm Limited (GB) | 2023-08-09 | — | — | EP | claimed |
| EP-3219335-B1 | COATING COMPOSITION AND MEDICAL DEVICE | TERUMO CORP (JP) | 2018-12-19 | — | — | EP | claimed |
| CN-105211672-B | A kind of hypersensitive method of reduction river crab meat | 江苏省农业科学院 | 2018-11-02 | — | — | CN | claimed |
| EP-3219335-A1 | COATING COMPOSITION AND MEDICAL DEVICE | Terumo Kabushiki Kaisha (JP) | 2017-09-20 | — | — | EP | claimed |
| US-20170143663-A1 | COATING COMPOSITION AND MEDICAL DEVICE | TERUMO KABUSHIKI KAISHA (JP) | 2017-05-25 | — | — | US | claimed |
| EP-2813250-B1 | COATING COMPOSITION AND MEDICAL DEVICE | TERUMO CORP (JP) | 2017-05-03 | — | — | EP | claimed |
| CN-104203297-B | Coating composition and medical device | TERUMO CORP. (JP) | 2016-04-06 | — | — | CN | claimed |
| US-20150056265-A1 | COATING COMPOSITION AND MEDICAL DEVICE | TERUMO KABUSHIKI KAISHA (JP) | 2015-02-26 | — | — | US | claimed |
| EP-2813250-A1 | COATING COMPOSITION AND MEDICAL DEVICE | Terumo Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | claimed |
| US-20120178114-A1 | METHODS AND DEVICES FOR DETECTING THROMBIN GENERATION | SUBC, INC. (US) | 2012-07-12 | — | — | US | claimed |
| WO-2009023538-A1 | METHODS AND DEVICES FOR DETECTING THROMBIN GENERATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-02-19 | — | — | WO | claimed |
| US-12559570-B2 | Anti-PAD2 antibody | PHARMA FOODS INTERNATIONAL CO., LTD. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20250236683-A1 | COMPOSITION AND METHOD FOR INHIBITING FIBROSIS | PHARMA FOODS INTERNATIONAL CO., LTD. (JP) | 2025-07-24 | — | — | US | disclosed |
| EP-4501354-A1 | COMPOSITION AND METHOD FOR INHIBITING FIBROSIS | Pharma Foods International Co., Ltd. (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20240309112-A1 | NOVEL ANTI-PAD4 ANTIBODY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-09-19 | — | — | US | disclosed |
| US-4234477-A | DIAGNOSTIC DETERMINATION OF A HYDROLASE, CALLICREIN | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
| US-4138292-A | ENZYMES OR MICROORGANISMS IN A SULFATED POLYSACCHARIDE GEL | TANABE SEIYAKU CO., LTD. (JP) | 1979-02-06 | — | — | US | disclosed |
| US-4014860-A | Plasminostreptin (enzyme inhibitor) and method for producing it from streptomyces | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-03-29 | — | — | US | disclosed |
| US-3983001-A | Isolation of biologically active compounds by affinity chromatography | CESKOSLOVENSKA AKADEMIE VED (CS) | 1976-09-28 | — | — | US | disclosed |
| US-3959080-A | Carrier matrix for the fixation of biochemically effective substances and process for the preparation thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559570-B2 | Anti-PAD2 antibody | PADI2, PADI1, PADI4 | BCHE 2229/4885ACHE 3055/4885CYP26A1 1876/4885 |
| US-20170143663-A1 | COATING COMPOSITION AND MEDICAL DEVICE | SLC6A19, SLC7A1, SLC38A7 | BCHE 746/4885ACHE 3037/4885CYP26A1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.